Repare Therapeutics jumps on cancer drug licensing deal

Repare Therapeutics

15/07/2025 21:23

** Shares of drug developer Repare Therapeutics RPTX.O rise 18% to $1.68 in extended trading

** RPTX licensed its cancer drug, lunresertib, to Swiss-based private firm Debiopharm for worldwide development and commercialization

** RPTX will receive $10 million upfront and could earn up to $257 million in milestone payments and royalties

** Debiopharm plans to combine lunresertib with its own drug Debio 0123 for cancer treatment

** Stock up 9.2% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))